Abstract
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years and adolescents 12 to><18 years with episodic migraine. the study hypothesis is that in pediatric subjects with episodic migraine the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 month 3 in monthly migraine days mmds when compared with placebo in the double-blind treatment phase dbtp.>
